| Combination of | |
|---|---|
| Elvitegravir | Integrase inhibitor |
| Cobicistat | Cytochrome P450 inhibitor |
| Emtricitabine | Reverse-transcriptase inhibitor |
| Tenofovir disoproxil | Reverse-transcriptase inhibitor |
| Clinical data | |
| Trade names | Stribild |
| AHFS/Drugs.com | Professional Drug Facts |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
Elvitegravir/cobicistat/emtricitabine/tenofovir, sold under the brand name Stribild, also known as the Quad pill, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir disoproxil directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir. It is taken by mouth. It is manufactured by Gilead Sciences.
Serum creatinine (a marker of kidney function) may increase with use of elvitegravir/cobicistat/emtricitabine/tenofovir. This is caused by cobicistat's inhibition of tubular secretion in the nephron.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Stribild- elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 16 September 2021. Retrieved 24 July 2024.
- ^ "Stribild EPAR". European Medicines Agency. 13 June 2013. Retrieved 24 July 2024.